NSCLC	non-small cell lung cancer
EGFR	epidermal growth factor receptor
TKI	tyrosine kinase inhibitor
PFS	progression-free survival
FGFR	fibroblast growth factor receptor
IGF1R	insulin-like growth factor 1 receptor
AXL	anexelekto
ALK	anaplastic lymphoma kina
EML4	echinoderm microtubule-associated protein-like 4
MET	mesenchymal-epithelial transition
ORR	objective response rate
KIT	mast/stem cell growth factor receptor
RTK	receptor tyrosine kinase
HGF	hepatocyte growth factor
FDA	Food and Drug Administration
VEGF	vascular endothelial growth factor
IFL	irinotecan, bolus fluorouracil, and leucovorin
FOLFOX4	oxaliplatin, fluorouracil, and leucovorin
FOLFIRI	5-fluorouracil, leucovorin, and irinotecan
VEGFR	VEGF receptor
ADCC	antibody-dependent cellular cytotoxicity
TGF-β	transforming growth factor-beta
TβRI	TGFβ receptor I
HER2	human epidermal growth factor receptor 2
TMB	tumor mutational burden
MSI-H	microsatellite instability-high
dMMR	deficient mismatch repair
AR	androgen receptor
DHT	dihydrotestosterone
LHRH	luteinizing hormone-releasing hormone
CAB	complete androgen blockade
ADT	androgen deprivation therapy
DHEA	dehydroepiandrosterone
mCRPC	metastatic castration-resistant prostate cancer
nmCRPC	non-metastatic castration-resistant prostate cancer
mHSPC	metastatic hormone-sensitive prostate cancer
mCSPC	metastatic castration-sensitive prostate cancer
HRR	homologous recombination repair
DDR	DNA damage response
NHEJ	non-homologous end joining
MMR	mismatch repair
PSA	prostate specific antigen
NDA	new drug application
PSMA	prostate-specific membrane antigen
MAPK	mitogen-activated protein kinase
CDK12	cyclin-dependent kinase 12
ICI	immune checkpoint inhibitor
HRD	homologous recombination deficiency